EphA4 Antibodies

Details EphA4 Antibodies EphA4 Antibodies

2004-06-07

2009-10-20

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S143100, C424S174100, C530S387100, C530S388100, C530S388800

Reexamination Certificate

active

07604799

ABSTRACT:
The invention provides agonistic anti-EphA4 antibodies.

REFERENCES:
patent: 5322798 (1994-06-01), Sadowski
patent: 5341215 (1994-08-01), Seher
patent: 6268125 (2001-07-01), Perkins
patent: 6289286 (2001-09-01), Andersson et al.
patent: 6373577 (2002-04-01), Brauer et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 2003/0224374 (2003-12-01), Dai et al.
patent: 2004/0028685 (2004-02-01), Kinch et al.
patent: 2004/0180823 (2004-09-01), Pasquale et al.
patent: WO 99/54440 (1999-10-01), None
patent: WO 01/00678 (2001-01-01), None
patent: WO 01/94629 (2001-12-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320)
Kipps et al (J Exp Med, 1988, 167:840-852).
Easty et al (Int J Cancer, 1997, 71:1061-1065, IDS).
iHOP, EphA4, 2 pages.
Rudikoff et al, PNAS, USA, 1982, 79: 1979-1983.
Panka et al (Proc Natl Acad Sci, 1988, 85:3080-3084).
MacCallum et al (J Mol Biology, 1996, 262:732-745).
Easty et al (Int J Cancer, 1997, 71:1061-1065, IDS).
iHOP, p.1.
Freitas et al, Dev Genes Evol, 2004, 214:466-472.
Kultima et al (BMC Bioinformatics, 2006, 7:475, internet pp. 1-27).
Sambrook et al. (Molecular Cloning, 2nd edition, Cold Spring Harbor Press, 1989, p. 18.47).
Invitrogen™ product information sheet for protein standards and ladders, p. 1-4.
Wada et al (Developmental Biology, 1998, 202:244-252).
U.S. Appl. No. 60/622,711, filed Oct. 27, 2004, Kinch.
U.S. Appl. No. 60/503,356, filed Sep. 16, 2003, Carles-Kinch et al.
U.S. Appl. No. 60/476,909, filed Jun. 6, 2003, Carles-Kinch et al.
U.S. Appl. No. 09/952,560, filed Sep. 12, 2001, Kilpatrick et al.
Ashida et al., 2004, “Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs,” Cancer Res. 64(17):5963-5972.
Burridge et al., 1996, “Focal adhesions, contractility, and signaling,” Annu. Rev. Cell Dev. Biol. 12:463-518.
Cance et al., 1995, “Protein kinases in human breast cancer,” Breast Cancer Res. Treat. 35(1):105-114.
Chaiken et al., 1992, “Analysis of macromolecular interactions using immobilized ligands,” Anal. Biochem. 201(2):197-210.
Cheng et al., 2002, “The ephrins and Eph receptors in angiogenesis,” Cytokine Growth Factor Rev. 13(1):75-85.
Dong et al., 2002, “Some new aspects in biosensors,” J. Biotechnol. 82(4):303-323.
Easty et al., 1997, “Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma,” Int. J. Cancer 71(6):1061-1065.
Ellis et al., 1996, “A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn,” Oncogene 12(8):1727-1736.
Fisher et al., 1994, “Surface plasmon resonance based methods for measuring the kinetics and binding affinities of biomolecular interactions,” Curr. Opin. Biotechnol. 5(4):389-395.
Fivash et al., 1998, “BIAcore for macromolecular interaction,” Curr. Opin. Biotechnol. 9(1):97-101.
Fox et al., 1995, “cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases,” Oncogene 10(5):897-905.
Fry et al., 1995, “Inhibitors of protein tyrosine kinases,” Curr. Opin. Biotechnol. 6(6):662-667.
Haseloff et al., 1988, “Simple RNA enzymes with new and highly specific endoribonuclease activities,” Nature 334(6183):585-591.
Hunter, 1997, “Oncoprotein networks,” Cell 88(3):333-346.
Kinch et al., 2003, “Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer,” Clin. Exp. Metastasis 20(1):59-68.
Kondapaka et al., 1996, “Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer,” Mol. Cell. Endocrinol. 117(1):53-58.
Kuang et al., 1998, “Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line,” Nucleic Acids Res. 26(4):1116-1123.
Levitzki et al., 1995, “Tyrosine kinase inhibition: an approach to drug development,” Science 267(5205):1782-1788.
Logsdon et al., 2003, “Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer,” Cancer Res. 63(10):2649-2657.
Malik et al., 1996, “Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases,” Biochim. Biophys. Acta 1287(2-3):73-76.
Martone et al., 1997, “Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system,” Brain Res. 771(2):238-250.
Meric et al., 2002, “Expression profile of tyrosine kinases in breast cancer,” Clin. Cancer. Res. 8(2):361-367.
Miao et al., 2000, “Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation,” Nat. Cell Biol. 2(2):62-69.
Morton et al., 1995, “Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration,” Anal. Biochem. 227(1):176-185.
Mullett et al., 2000, “Surface plasmon resonance-based immunoassays,” Methods 22(1):77-91.
Myszka, 1997, “Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors,” Curr. Opin. Biotechnol. 8(1):50-57.
Nemoto et al., 1997, “Overexpression of protein tyrosine kinases in human esophageal cancer,” Pathobiology 65(4):195-203.
O'Shannessy, 1994, “Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: a critique of the surface plasmon resonance literature,” Curr. Opin. Biotechnol. 5(1):65-71.
Parsons, 1996, “Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins,” Curr. Opin. Cell Biol. 8(2):146-152.
Pasquale, 1997, “The Eph family receptors,” Curr. Opin. Cell. Biol. 9(5):608-615.
Patarca, 1996, “Protein phosphorylation and dephosphorylation in physiologic and oncologic processes,” Crit. Rev. Oncog. 7(5-6):343-432.
Rhim et al., 1997, “Human prostate carcinogenesis,” Crit. Rev. Oncog. 8(4):305-328.
Rich et al., 2000, “Advances in surface plasmon resonance biosensor analysis,” Curr. Opin. Biotechnol. 11(1):54-61.
Winning et al., 2002, “EphA4 catalytic activity causes inhibition of RhoA GTPase in Xenopus laevis embryos,” Differentiation 70(1):46-55.
Zelinski et al., 2001, “EphA2 overexpression causes tumorigenesis of mammary epithelial cells,” Cancer Res. 61(5):2301-2306.

Affiliated with

Also associated with

Rating

EphA4 Antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EphA4 Antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphA4 Antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143790